PIIPPI (NCT04364802).

Study name	'COVID‐19: povidone‐iodine intranasal prophylaxis in front‐line healthcare personnel and inpatients (PIIPPI)'
Methods	Non‐randomised clinical trial
Participants	Frontline healthcare workers who are negative for COVID‐19 or hospital inpatients (who have a hospitalisation of more than 7 days, or who are set to undergo a significant surgical procedure), aged 18 to 99 years Inclusion criteria: Healthcare worker OR patient with expected hospital stay of 7+ days OR patient admitted for major surgery COVID‐19 negative by nasal swab test Asymptomatic for COVID‐19 Able to consent to participation Exclusion criteria: Positive for COVID‐19 by nasal swab Symptomatic for COVID‐19 Unable to consent Planned sample size: 250 participants
Interventions	Intervention group: For healthcare workers: povidone‐iodine nasal spray and gargle (10% diluted 1:30) will be used at the beginning of their shift, in the middle and at the end of their shift For hospital inpatients: povidone‐iodine nasal spray and gargle (10% diluted 1:30) for patient participants to use shortly after admission or pre‐operatively (no further details provided) Comparator group: No intervention Use of additional interventions for both study groups: Standard PPE and a pre‐ and post‐study test for COVID‐19
Outcomes	Primary outcomes: Percentage of healthcare workers testing positive for COVID‐19; time frame: 3 weeks Percentage of patients testing positive for COVID‐19; time frame: 2 weeks Secondary outcomes: PVP‐I ease of use; time frame: 3 weeks PVP‐I comfort; time frame: 3 weeks Adherence to treatment protocol; time frame: 3 weeks
Starting date	May 2020
Contact information	Alexandra Kejner Email: alexandra.kejner@uky.edu
Notes	Trial registered in USA Estimated completion date: May 2021

BIPAP: bilevel positive airway pressure; COVID‐19 coronavirus disease 2019; CPAP: continuous positive airway pressure; PCR: polymerase chain reaction; PPE: personal protective equipment; PVP‐I povidone iodine; RCT: randomised controlled trial; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2